Two-Drug attack on Tough-to-Treat blood cancer
NCT ID NCT03467867
Summary
This study is testing a combination of two drugs, venetoclax and rituximab, for adults with chronic lymphocytic leukemia (CLL) that has returned or stopped responding to other treatments. The goal is to see how well and how safely this drug pair can control the cancer. Researchers will measure how many patients respond to treatment and how long the response lasts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.